Psyence Group PSYGF and Filament Health Corp. FLHLF announced the signing of a licensing agreement: Filament is to license its proprietary psilocybin derived drug, PEX010, and the associated IP to Psyence for use in its upcoming clinical trials.
Thanks to this license, Psyence will have exclusivity for the drug in the United Kingdom for studying its effects on anxiety and depression and associated ailments within the context of palliative care.
Psyence will provide the mushrooms, while Filament will process the raw material and manufacture a dosage form for use in future clinical trials.
Earlier this year, Filament signed a licensing agreement for PEX010 with private therapeutic bioscience company Cybin Therapeutics.
At the moment, Filament's proprietary drug has received authorization from the FDA and Health Canada to enter into Phase 1 and Phase 2 clinical trials.
Photo: Courtesy of Marco Allegretti on Unsplash.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving—don’t get left behind!
Curious about what’s next for the industry and how to stay ahead in today’s competitive market?
Join top executives, investors, and industry leaders at the Benzinga Cannabis Capital Conference in Chicago on June 9-10. Dive deep into market-shaping strategies, investment trends, and brand-building insights that will define the future of cannabis.
Secure your spot now before prices go up—this is where the biggest deals and connections happen!
